The National Institute for Health and Care Excellence (NICE) has recommended Talvey (talquetamab) for use in the NHS for treating relapsed or refractory myeloma (RRMM) in adults. Talquetamab, developed by Johnson & Johnson, is a first-in-class bispecific antibody targeting the GPRC5D receptor on myeloma cells. The treatment redirects T-cells to the GPRC5D-expressing myeloma cells, activating […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!